n-Butyl 5-formyl-2-hydroxybenzoate | 179002-93-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: n-Butyl 5-formyl-2-hydroxybenzoate
• 英文别名: butyl 5-formyl-2-hydroxybenzoate
• CAS: 179002-93-8
• 化学式: C₁₂H₁₄O₄
• 分子量: 222.241
• InChiKey: LFAILDUKWLSXTC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  n-Butyl 5-formyl-2-hydroxybenzoate 在 一水合肼 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 以82.3%的产率得到
  参考文献：
  名称：

  POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTALLINE POLYMER, AND OPTICALLY ANISOTROPIC MATERIAL

  摘要：

  公开号：

  EP2143710B1
• 作为产物：
  描述：

  5-甲酰水杨酸 、 正丁醇 在 4-二甲氨基吡啶 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 为溶剂， 以63.8%的产率得到n-Butyl 5-formyl-2-hydroxybenzoate
  参考文献：
  名称：

  POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTALLINE POLYMER, AND OPTICALLY ANISOTROPIC MATERIAL

  摘要：

  公开号：

  EP2143710B1

文献信息

• [EN] CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO<br/>[FR] CONJUGUÉS COMPRENANT DES GROUPES PEPTIDIQUES ET PROCÉDÉS ASSOCIÉS À CEUX-CI
  申请人：LEGOCHEM BIOSCIENCES INC

  公开号：WO2017089894A1

  公开（公告）日：2017-06-01

  In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

  在某些方面，本发明涉及一种抗体药物偶联物，包括：抗体；连接体；以及至少两个活性剂。在优选的实施例中，连接体包括由多个氨基酸组成的肽序列，其中至少两个活性剂通过共价键与氨基酸的侧链连接。抗体药物偶联物可以包括自焚基团，优选地是两个自焚基团。连接体可以包括O-取代的肟，例如，其中肟的氧原子被取代以与活性剂形成共价键连接；肟的碳原子被取代以与抗体形成共价键连接。
• Aromatic compounds containing basic and acidic termini useful as
  申请人：The Du Pont Merck Pharmaceutical Company

  公开号：US05523302A1

  公开（公告）日：1996-06-04

  This invention relates to novel compounds containing basic and acidic termini, pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.

  这项发明涉及含有碱性和酸性末端的新化合物，含有这类化合物的药物组合物，制备这类化合物的方法，以及使用这些化合物的方法，单独或与其他治疗剂联合使用，用于抑制血小板聚集，作为溶栓剂，和/或用于治疗血栓栓塞性疾病。
• POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTALLINE POLYMER, AND OPTICAL ANISOTROPIC ARTICLE
  申请人：Sakamoto Kei

  公开号：US20100258764A1

  公开（公告）日：2010-10-14

  A polymerizable liquid crystal compound shown by the following formula (I), a polymerizable liquid crystal composition that includes the polymerizable liquid crystal compound and a chiral compound polymerizable with the polymerizable liquid crystal compound, a liquid crystalline polymer obtained by polymerizing the polymerizable liquid crystal compound or the polymerizable liquid crystal composition, and an optical anisotropic article that includes the liquid crystalline polymer. The polymerizable liquid crystal compound shows a liquid crystal phase over a wider temperature range, is chemically stable, can be inexpensively produced, and has a wide selective reflection wavelength band Δλ (i.e., a large value Δn). The polymerizable liquid crystal composition includes the polymerizable liquid crystal compound, the liquid crystalline polymer is obtained by polymerizing the polymerizable liquid crystal compound or the polymerizable liquid crystal composition, and the optical anisotropic article includes the liquid crystalline polymer. wherein Y 1 to Y 6 represent —O—, —O—C(═O)—, —C(═O)—O—, or the like, G 1 and G 2 represent divalent aliphatic groups having 1 to 20 carbon atoms, Z 1 and Z 2 represent an alkenyl group having 2 to 10 carbon atoms or the like, A 1 and A 2 represent divalent organic groups A having 1 to 30 carbon atoms, X 1 to X 8 represent a hydrogen atom or the like, and a and b represent 0 or 1.
• US8158021B2
  申请人：——

  公开号：US8158021B2

  公开（公告）日：2012-04-17
• [EN] CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO<br/>[FR] CONJUGUÉS COMPRENANT DES GROUPES AUTO-IMMOLABLES ET PROCÉDÉS ASSOCIÉS
  申请人：LEGOCHEM BIOSCIENCES INC

  公开号：WO2017089890A1

  公开（公告）日：2017-06-01

  In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self- immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.